董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jane H. Hollingsworth | 女 | Director | 63 | 12.70万美元 | 未持股 | 2021-04-30 |
| David G. Kalergis | 男 | Chairman of the Board | 72 | 96.29万美元 | 未持股 | 2021-04-30 |
| Robert Adams | 男 | Director | 70 | 10.98万美元 | 未持股 | 2021-04-30 |
| Mark T. Giles | 男 | Director | 66 | 11.39万美元 | 未持股 | 2021-04-30 |
| Alan Levin | 男 | Director | 57 | 11.23万美元 | 未持股 | 2021-04-30 |
| Robert J. Cobuzzi, Jr. | 男 | Director,President and Chief Executive Officer | 56 | 163.50万美元 | 未持股 | 2021-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Cobuzzi, Jr. | 男 | Director,President and Chief Executive Officer | 56 | 163.50万美元 | 未持股 | 2021-04-30 |
| William K. Hornung | 男 | Chief Financial Officer | 52 | 54.00万美元 | 未持股 | 2021-04-30 |
| Christopher D. Galloway | 男 | Chief Medical Officer | 50 | 29.98万美元 | 未持股 | 2021-04-30 |
| William R. Elder | 男 | General Counsel,Corporate Secretary | 38 | 26.57万美元 | 未持股 | 2021-04-30 |
董事简历
中英对照 | 中文 | 英文- Jane H. Hollingsworth
-
Jane H. Hollingsworth，2014年8月起，担任本公司董事。2013年10月至今，她一直担任Militia Hill Ventures LLC的管理合伙人、Immunome Inc.的执行董事长，前者是私营的生命科学行业加速器，后者是私营的肿瘤免疫治疗公司。2012年10月至2013年12月，她担任JHH Technologies LLC的总裁，这是提供医疗健康咨询服务的私营企业。2005年1月至2007年9月，她是 NuPathe Inc的首席执行官、联合创始人，这是专注于中枢神经系统疾病的上市制药企业。加入 NuPathe Inc之前，她曾是：上市制药企业Auxilium Pharmaceuticals的执行副总裁、联合创始人；IBAH Inc的副总裁、秘书、法律总顾问，这是一个上市的临床研究机构，在1998年被出售给Omnicare Inc.职业生涯之初，她是律师事务所Montgomery, McCracken, Walker & Rhoads的一名商业诉讼律师，后来曾担任美国特拉华州地区法院Honorable Jane R. Roth的法务助理。她在Gettysburg College获得西班牙语学士学位，在Villanova University获得法律博士学位。
Jane H. Hollingsworth has served as a director since September 2020. She currently serves as Managing Partner of Militia Hill Ventures, an investment firm focused on building, growing and investing in high-quality life sciences companies, a role she has held since Militia Hill's founding in 2013. Prior to founding Militia Hill, Ms. Hollingsworth served as Executive Chair of Immunonome Inc., a cancer immunotherapy company, and co-founder and Chief Executive Officer of NuPathe, Inc., a publicly-traded biopharmaceutical company focused on diseases of the central nervous system, prior to the acquisition of NuPathe by Teva Pharmaceuticals in 2014. She also currently serves on the board of various industry and community organizations, including DS Biopharma, the University City Science Center, the Kimmel Center for the Performing Arts and Breatcancer.Org. Ms. Hollingsworth received her B.A. from Gettysburg College and her J.D. from Villanova University. - Jane H. Hollingsworth，2014年8月起，担任本公司董事。2013年10月至今，她一直担任Militia Hill Ventures LLC的管理合伙人、Immunome Inc.的执行董事长，前者是私营的生命科学行业加速器，后者是私营的肿瘤免疫治疗公司。2012年10月至2013年12月，她担任JHH Technologies LLC的总裁，这是提供医疗健康咨询服务的私营企业。2005年1月至2007年9月，她是 NuPathe Inc的首席执行官、联合创始人，这是专注于中枢神经系统疾病的上市制药企业。加入 NuPathe Inc之前，她曾是：上市制药企业Auxilium Pharmaceuticals的执行副总裁、联合创始人；IBAH Inc的副总裁、秘书、法律总顾问，这是一个上市的临床研究机构，在1998年被出售给Omnicare Inc.职业生涯之初，她是律师事务所Montgomery, McCracken, Walker & Rhoads的一名商业诉讼律师，后来曾担任美国特拉华州地区法院Honorable Jane R. Roth的法务助理。她在Gettysburg College获得西班牙语学士学位，在Villanova University获得法律博士学位。
- Jane H. Hollingsworth has served as a director since September 2020. She currently serves as Managing Partner of Militia Hill Ventures, an investment firm focused on building, growing and investing in high-quality life sciences companies, a role she has held since Militia Hill's founding in 2013. Prior to founding Militia Hill, Ms. Hollingsworth served as Executive Chair of Immunonome Inc., a cancer immunotherapy company, and co-founder and Chief Executive Officer of NuPathe, Inc., a publicly-traded biopharmaceutical company focused on diseases of the central nervous system, prior to the acquisition of NuPathe by Teva Pharmaceuticals in 2014. She also currently serves on the board of various industry and community organizations, including DS Biopharma, the University City Science Center, the Kimmel Center for the Performing Arts and Breatcancer.Org. Ms. Hollingsworth received her B.A. from Gettysburg College and her J.D. from Villanova University.
- David G. Kalergis
-
David G. Kalergis，担任我们的董事长、首席执行官和我们的董事。基于公司合并，他被任命为董事长兼首席执行官。他与Gainer博士是Diffusion LLC的联席创始人，也曾担任Diffusion LLC的董事（2001年公司创立至2016年1月），也曾担任Diffusion LLC公司的首席执行官（2004年以来）。加入Diffusion LLC之前，他曾任职the University of Virginia，担任Pharmaceutical Research Associates, Inc.（一个制药合同研究组织）的总法律顾问和商业开发主管，以及美国政府和Dewey, Ballantine, Bushby, Palmer & Wood律师事务所的情报分析员，从事企业融资、公开发行和并购领域。此外，他曾任职于Virginia National Bank的董事会和审计委员会（1998年7月至2012年5月）。他持有the University of Virginia的心理学学士学位、工商管理硕士学位、法学博士学位。他毕业于the Harvard Business School的制药和生物技术产业领导力和战略项目。
David G. Kalergis has served as our Chairman of the Board and Chief Executive Officer since the completion of the Merger. Mr. Kalergis, along with Dr. Gainer, is the Company’s co-founder and has served as a director of Diffusion LLC since its inception in 2001 and as its Chief Executive Officer since 2004. Prior to joining the Diffusion LLC, Mr. Kalergis held positions with the University of Virginia, as the general counsel and director of business development for Pharmaceutical Research Associates, Inc., a pharmaceutical contract research organization, as an intelligence analyst for the U.S. Government and with the law firm Dewey, Ballantine, Bushby, Palmer & Wood, practicing in the areas of corporate finance, public offerings and mergers and acquisitions. In addition, from July 1998 until May 2012 Mr. Kalergis served on the board of directors and audit committee of Virginia National Bank. Mr. Kalergis received a B.A. in psychology, as well as an M.B.A. and J.D., from the University of Virginia, and is a graduate of the Harvard Business School’s Leadership and Strategy in the Pharmaceutical and Biotechnology Industry program. - David G. Kalergis，担任我们的董事长、首席执行官和我们的董事。基于公司合并，他被任命为董事长兼首席执行官。他与Gainer博士是Diffusion LLC的联席创始人，也曾担任Diffusion LLC的董事（2001年公司创立至2016年1月），也曾担任Diffusion LLC公司的首席执行官（2004年以来）。加入Diffusion LLC之前，他曾任职the University of Virginia，担任Pharmaceutical Research Associates, Inc.（一个制药合同研究组织）的总法律顾问和商业开发主管，以及美国政府和Dewey, Ballantine, Bushby, Palmer & Wood律师事务所的情报分析员，从事企业融资、公开发行和并购领域。此外，他曾任职于Virginia National Bank的董事会和审计委员会（1998年7月至2012年5月）。他持有the University of Virginia的心理学学士学位、工商管理硕士学位、法学博士学位。他毕业于the Harvard Business School的制药和生物技术产业领导力和战略项目。
- David G. Kalergis has served as our Chairman of the Board and Chief Executive Officer since the completion of the Merger. Mr. Kalergis, along with Dr. Gainer, is the Company’s co-founder and has served as a director of Diffusion LLC since its inception in 2001 and as its Chief Executive Officer since 2004. Prior to joining the Diffusion LLC, Mr. Kalergis held positions with the University of Virginia, as the general counsel and director of business development for Pharmaceutical Research Associates, Inc., a pharmaceutical contract research organization, as an intelligence analyst for the U.S. Government and with the law firm Dewey, Ballantine, Bushby, Palmer & Wood, practicing in the areas of corporate finance, public offerings and mergers and acquisitions. In addition, from July 1998 until May 2012 Mr. Kalergis served on the board of directors and audit committee of Virginia National Bank. Mr. Kalergis received a B.A. in psychology, as well as an M.B.A. and J.D., from the University of Virginia, and is a graduate of the Harvard Business School’s Leadership and Strategy in the Pharmaceutical and Biotechnology Industry program.
- Robert Adams
-
Robert Adams，担任我们的董事之一。他被任命为董事，基于公司合并完成，此前曾担任Diffusion LLC的董事（2002年至2016年1月）。2015年退休之前，他曾担任Nixon & Vanderhye P.C（知识产权律师事务所）的合伙人，在那里他曾实践25年以上，专注于专利诉讼和国际专利实施许可和谈判。期间，他曾担任50多个主要知识产权诉讼的首席诉讼律师，在那里他曾代表他的美国和外国客户直接领导所有知识产权估值和定居点。此外，他曾担任一个著名日本消费产品公司的谈判者15年，涉及多种复杂许可情境。这些谈判通常涉及美国和外国专利交叉许可的数以百计的专利。他代表客户的领导授权活动包括Texas Instruments、Advanced Micro Devices、Freescale的多年的谈判。他持有the University of Maryland的学士学位，以及George Washington University的荣誉法学博士学位。他是the Virginia State Bar的成员。
Robert Adams has served as a director since January 2016 and as a director of Diffusion LLC since 2002. Prior to his retirement in 2015 Mr. Adams was a partner in the intellectual property law firm of Nixon & Vanderhye P.C, where he had practiced for over 25 years, focusing on patent litigation and international patent licensing and negotiations. During that time period, Mr. Adams was lead litigation counsel in more than 50 major intellectual property lawsuits, where he directly handled, for example, all intellectual property valuations and settlements on behalf of his U.S. and foreign clients. Moreover, Mr. Adams served as the head negotiator for a well-known Japanese consumer products company for 15 years in various complicated licensing situations. Those negotiations typically involved the cross-licensing of up to hundreds of U.S. and foreign patent rights. His lead licensing activities on behalf of that client included, among other things, multi-year negotiations with Texas Instruments, Advanced Micro Devices and Freescale. Mr. Adams received a B.A. from the University of Maryland and a J.D. from George Washington University with honors, and is a member of the Virginia State Bar. - Robert Adams，担任我们的董事之一。他被任命为董事，基于公司合并完成，此前曾担任Diffusion LLC的董事（2002年至2016年1月）。2015年退休之前，他曾担任Nixon & Vanderhye P.C（知识产权律师事务所）的合伙人，在那里他曾实践25年以上，专注于专利诉讼和国际专利实施许可和谈判。期间，他曾担任50多个主要知识产权诉讼的首席诉讼律师，在那里他曾代表他的美国和外国客户直接领导所有知识产权估值和定居点。此外，他曾担任一个著名日本消费产品公司的谈判者15年，涉及多种复杂许可情境。这些谈判通常涉及美国和外国专利交叉许可的数以百计的专利。他代表客户的领导授权活动包括Texas Instruments、Advanced Micro Devices、Freescale的多年的谈判。他持有the University of Maryland的学士学位，以及George Washington University的荣誉法学博士学位。他是the Virginia State Bar的成员。
- Robert Adams has served as a director since January 2016 and as a director of Diffusion LLC since 2002. Prior to his retirement in 2015 Mr. Adams was a partner in the intellectual property law firm of Nixon & Vanderhye P.C, where he had practiced for over 25 years, focusing on patent litigation and international patent licensing and negotiations. During that time period, Mr. Adams was lead litigation counsel in more than 50 major intellectual property lawsuits, where he directly handled, for example, all intellectual property valuations and settlements on behalf of his U.S. and foreign clients. Moreover, Mr. Adams served as the head negotiator for a well-known Japanese consumer products company for 15 years in various complicated licensing situations. Those negotiations typically involved the cross-licensing of up to hundreds of U.S. and foreign patent rights. His lead licensing activities on behalf of that client included, among other things, multi-year negotiations with Texas Instruments, Advanced Micro Devices and Freescale. Mr. Adams received a B.A. from the University of Maryland and a J.D. from George Washington University with honors, and is a member of the Virginia State Bar.
- Mark T. Giles
-
Mark T. Giles，担任我们的董事之一。他被任命为董事，基于公司合并完成，此前曾担任Diffusion LLC的董事（2008年至2016年1月）。2007年7月以来，他一直担任Panda Holdings, LLC（从事私人资本的投资和管理）的唯一管理成员。加入Panda Holdings公司之前，他曾担任Virginia National Bank的首席执行官、主席（1998年7月至2011年12月）。加入Virginia National Bank之前，他曾担任两个上市控股公司和德克萨斯州子公司银行的总裁，并在休斯顿的一家律师事务所的银行集团从事法律事务，也曾担任VNBTrust的主席。他是Walk2Campus Properties, LLC的创始主管，并主管Relay Foods, Inc.、Expedition Trust Company的董事会。他也任职于The Paramount Theater Foundation、The Paramount Theater Operating Company、 the Thomas Jefferson Area United Way、the Computers4Kids Program的董事会。他也任职于Martha Jefferson Hospital的医务委员会和财务委员会。他获得了弗吉尼亚大学麦金太尔商学院（the University of Virginia McIntire School of Commerce）的学士学位，以及弗吉尼亚大学法学院（the University of Virginia School of Law）的法学博士学位。
Mark T. Giles has served as a director since January 2016 and as a director of Diffusion LLC since 2008. Since July 2007 Mr. Giles has been the sole managing member of Panda Holdings, LLC, which engages in the investment and management of private capital. Since February 2015 Mr. Giles has been a general partner of Anchormark Holdings, LLC, which engages in the investment and management of private capital. Prior to joining Panda Holdings and Anchormark Holdings, Mr. Giles served as the Chief Executive Officer of Virginia National Bank from July 1998 until June 2007 and thereafter continued to serve as the non-executive Chairman until December 2011. Prior to joining Virginia National Bank, Mr. Giles also served as the president of two publicly traded bank holding companies and subsidiary banks in Texas and practiced law with the banking group of a Houston law firm. He chairs the board of Expedition Trust Company. Mr. Giles received a B.S. from the McIntire School of Commerce at the University of Virginia and a J.D. from the University of Virginia School of Law. - Mark T. Giles，担任我们的董事之一。他被任命为董事，基于公司合并完成，此前曾担任Diffusion LLC的董事（2008年至2016年1月）。2007年7月以来，他一直担任Panda Holdings, LLC（从事私人资本的投资和管理）的唯一管理成员。加入Panda Holdings公司之前，他曾担任Virginia National Bank的首席执行官、主席（1998年7月至2011年12月）。加入Virginia National Bank之前，他曾担任两个上市控股公司和德克萨斯州子公司银行的总裁，并在休斯顿的一家律师事务所的银行集团从事法律事务，也曾担任VNBTrust的主席。他是Walk2Campus Properties, LLC的创始主管，并主管Relay Foods, Inc.、Expedition Trust Company的董事会。他也任职于The Paramount Theater Foundation、The Paramount Theater Operating Company、 the Thomas Jefferson Area United Way、the Computers4Kids Program的董事会。他也任职于Martha Jefferson Hospital的医务委员会和财务委员会。他获得了弗吉尼亚大学麦金太尔商学院（the University of Virginia McIntire School of Commerce）的学士学位，以及弗吉尼亚大学法学院（the University of Virginia School of Law）的法学博士学位。
- Mark T. Giles has served as a director since January 2016 and as a director of Diffusion LLC since 2008. Since July 2007 Mr. Giles has been the sole managing member of Panda Holdings, LLC, which engages in the investment and management of private capital. Since February 2015 Mr. Giles has been a general partner of Anchormark Holdings, LLC, which engages in the investment and management of private capital. Prior to joining Panda Holdings and Anchormark Holdings, Mr. Giles served as the Chief Executive Officer of Virginia National Bank from July 1998 until June 2007 and thereafter continued to serve as the non-executive Chairman until December 2011. Prior to joining Virginia National Bank, Mr. Giles also served as the president of two publicly traded bank holding companies and subsidiary banks in Texas and practiced law with the banking group of a Houston law firm. He chairs the board of Expedition Trust Company. Mr. Giles received a B.S. from the McIntire School of Commerce at the University of Virginia and a J.D. from the University of Virginia School of Law.
- Alan Levin
-
Alan Levin，担任我们的董事之一。基于公司合并，他被任命为董事。他曾担任Diffusion LLC的董事（从2015年6月到2016年1月）。他此前曾担任Endo Health Solutions Inc（Endo，全球专业医疗保健公司）的执行副总裁兼首席财务官（2009年6月至2013年9月退休）。加入Endo公司之前，他曾任职Texas Pacific Group（领先私人股本公司，他们的一个创业投资）。此前，他曾担任Pfizer, Inc的高级副总裁兼首席财务官，在那里他曾任职20年，担任多种执行职务，并不断被提拔，其中包括财务主管兼高级副总裁，负责财务和战略管理，涉及公司的研究开发组织。他持有Princeton University的学士学位，以及New York University’s Stern School of Business的硕士学位。他是注册会计师。他是Aceto Corp（纳斯达克上市公司，专注于仿制药和医药中间体产品）的董事会成员。他也是Auven Therapeutics（私人股本基金）的咨询委员会、the Critical Path Institute（美国食品和药物管理局和制药行业参与者之间的非营利组织的合作，专注于简化和加速发展和监管创新药的途径）的成员。
Alan Levin has served as a director since January 2016 and as a director of Diffusion LLC since June 2015. He previously served as Executive Vice President and Chief Financial Officer of Endo Health Solutions Inc., a global specialty healthcare company, from June 2009 until his retirement in September 2013. Prior to joining Endo, Mr. Levin worked with Texas Pacific Group, a leading private equity firm, and one of their start-up investments. Before that, he was Senior Vice President & Chief Financial Officer of Pfizer, Inc. where he worked for 20 years in a variety of executive positions of increasing responsibility, including Treasurer and Senior Vice President of Finance & Strategic Management for the company's research and development organization. Mr. Levin received a bachelor's degree from Princeton University and a master's degree from New York University's Stern School of Business. Mr. Levin is a certified public accountant. Mr. Levin currently serves as a member of the board of directors of Biocryst Pharmaceuticals, Inc., a Nasdaq-traded biopharmaceuticals company. He is also a member of the Advisory Board of Auven Therapeutics, a private equity fund; and the Critical Path Institute, a nonprofit collaboration between the Food and Drug Administration and pharmaceutical industry participants focused on streamlining and accelerating the development and regulatory pathways for innovative medicines. From December 2013 to July 2019 he was a member of the board of directors of Aceto Corporation, a Nasdaq-traded company specialized in generics and pharmaceutical intermediate products. - Alan Levin，担任我们的董事之一。基于公司合并，他被任命为董事。他曾担任Diffusion LLC的董事（从2015年6月到2016年1月）。他此前曾担任Endo Health Solutions Inc（Endo，全球专业医疗保健公司）的执行副总裁兼首席财务官（2009年6月至2013年9月退休）。加入Endo公司之前，他曾任职Texas Pacific Group（领先私人股本公司，他们的一个创业投资）。此前，他曾担任Pfizer, Inc的高级副总裁兼首席财务官，在那里他曾任职20年，担任多种执行职务，并不断被提拔，其中包括财务主管兼高级副总裁，负责财务和战略管理，涉及公司的研究开发组织。他持有Princeton University的学士学位，以及New York University’s Stern School of Business的硕士学位。他是注册会计师。他是Aceto Corp（纳斯达克上市公司，专注于仿制药和医药中间体产品）的董事会成员。他也是Auven Therapeutics（私人股本基金）的咨询委员会、the Critical Path Institute（美国食品和药物管理局和制药行业参与者之间的非营利组织的合作，专注于简化和加速发展和监管创新药的途径）的成员。
- Alan Levin has served as a director since January 2016 and as a director of Diffusion LLC since June 2015. He previously served as Executive Vice President and Chief Financial Officer of Endo Health Solutions Inc., a global specialty healthcare company, from June 2009 until his retirement in September 2013. Prior to joining Endo, Mr. Levin worked with Texas Pacific Group, a leading private equity firm, and one of their start-up investments. Before that, he was Senior Vice President & Chief Financial Officer of Pfizer, Inc. where he worked for 20 years in a variety of executive positions of increasing responsibility, including Treasurer and Senior Vice President of Finance & Strategic Management for the company's research and development organization. Mr. Levin received a bachelor's degree from Princeton University and a master's degree from New York University's Stern School of Business. Mr. Levin is a certified public accountant. Mr. Levin currently serves as a member of the board of directors of Biocryst Pharmaceuticals, Inc., a Nasdaq-traded biopharmaceuticals company. He is also a member of the Advisory Board of Auven Therapeutics, a private equity fund; and the Critical Path Institute, a nonprofit collaboration between the Food and Drug Administration and pharmaceutical industry participants focused on streamlining and accelerating the development and regulatory pathways for innovative medicines. From December 2013 to July 2019 he was a member of the board of directors of Aceto Corporation, a Nasdaq-traded company specialized in generics and pharmaceutical intermediate products.
- Robert J. Cobuzzi, Jr.
-
Robert J.Cobuzzi，Jr.自2020年1月起担任董事，自2020年9月起担任我们的总裁兼首席执行官。在加入Diffusion之前，Cobuzzi博士于2019年1月至2020年4月担任费城儿童医院线粒体疾病研究计划的顾问，该医院是一家国际知名的儿童医院和研究中心，并担任Mitocureia，Inc.的总裁兼首席执行官，关联公司，从2019年7月至2020年7月。2005年至2018年，Cobuzzi博士在专业品牌和仿制药制造商Endo International plc担任过各种职务，最近担任Endo Ventures Ltd.的总裁。Cobuzzi博士目前担任Sunstone Life Science Ventures的业务开发委员会主席，这是一家早期阶段的专注于人类疗法的欧洲投资者。Cobuzzi博士在科尔比学院获得生物化学和艺术史学士学位，并在芝加哥洛约拉大学获得分子和细胞生物化学博士学位。他曾担任Roswell Park Cancer Institute的实验疗法博士后研究员。
Robert J. Cobuzzi, Jr. has served as a director since January 2020 and as our President and Chief Executive Officer since September 2020. Prior to joining Diffusion, Dr. Cobuzzi served as Advisor of the Mitochondrial Disease Research Program at the Children's Hospital of Philadelphia, an internationally recognized hospital and research center devoted to children, from January 2019 to April 2020 and as President and Chief Executive Officer of MitoCUREia, Inc., an affiliated company, from July 2019 to July 2020. From 2005 to 2018 Dr. Cobuzzi served in various roles at Endo International PLC, a specialty branded and generic pharmaceuticals manufacturer, most recently serving as President of Endo Ventures Ltd. Dr. Cobuzzi currently serves as Chairman of the Business Development Board of Sunstone Life Science Ventures, an early-stage, European focused investor in human therapeutics. Dr. Cobuzzi received his Bachelor of Arts in Biochemistry and Art History from Colby College and his Ph.D. in Molecular and Cellular Biochemistry from Loyola University Chicago. He served as a Post-doctoral Fellow in Experimental Therapeutics at Roswell Park Cancer Institute. - Robert J.Cobuzzi，Jr.自2020年1月起担任董事，自2020年9月起担任我们的总裁兼首席执行官。在加入Diffusion之前，Cobuzzi博士于2019年1月至2020年4月担任费城儿童医院线粒体疾病研究计划的顾问，该医院是一家国际知名的儿童医院和研究中心，并担任Mitocureia，Inc.的总裁兼首席执行官，关联公司，从2019年7月至2020年7月。2005年至2018年，Cobuzzi博士在专业品牌和仿制药制造商Endo International plc担任过各种职务，最近担任Endo Ventures Ltd.的总裁。Cobuzzi博士目前担任Sunstone Life Science Ventures的业务开发委员会主席，这是一家早期阶段的专注于人类疗法的欧洲投资者。Cobuzzi博士在科尔比学院获得生物化学和艺术史学士学位，并在芝加哥洛约拉大学获得分子和细胞生物化学博士学位。他曾担任Roswell Park Cancer Institute的实验疗法博士后研究员。
- Robert J. Cobuzzi, Jr. has served as a director since January 2020 and as our President and Chief Executive Officer since September 2020. Prior to joining Diffusion, Dr. Cobuzzi served as Advisor of the Mitochondrial Disease Research Program at the Children's Hospital of Philadelphia, an internationally recognized hospital and research center devoted to children, from January 2019 to April 2020 and as President and Chief Executive Officer of MitoCUREia, Inc., an affiliated company, from July 2019 to July 2020. From 2005 to 2018 Dr. Cobuzzi served in various roles at Endo International PLC, a specialty branded and generic pharmaceuticals manufacturer, most recently serving as President of Endo Ventures Ltd. Dr. Cobuzzi currently serves as Chairman of the Business Development Board of Sunstone Life Science Ventures, an early-stage, European focused investor in human therapeutics. Dr. Cobuzzi received his Bachelor of Arts in Biochemistry and Art History from Colby College and his Ph.D. in Molecular and Cellular Biochemistry from Loyola University Chicago. He served as a Post-doctoral Fellow in Experimental Therapeutics at Roswell Park Cancer Institute.
高管简历
中英对照 | 中文 | 英文- Robert J. Cobuzzi, Jr.
Robert J.Cobuzzi，Jr.自2020年1月起担任董事，自2020年9月起担任我们的总裁兼首席执行官。在加入Diffusion之前，Cobuzzi博士于2019年1月至2020年4月担任费城儿童医院线粒体疾病研究计划的顾问，该医院是一家国际知名的儿童医院和研究中心，并担任Mitocureia，Inc.的总裁兼首席执行官，关联公司，从2019年7月至2020年7月。2005年至2018年，Cobuzzi博士在专业品牌和仿制药制造商Endo International plc担任过各种职务，最近担任Endo Ventures Ltd.的总裁。Cobuzzi博士目前担任Sunstone Life Science Ventures的业务开发委员会主席，这是一家早期阶段的专注于人类疗法的欧洲投资者。Cobuzzi博士在科尔比学院获得生物化学和艺术史学士学位，并在芝加哥洛约拉大学获得分子和细胞生物化学博士学位。他曾担任Roswell Park Cancer Institute的实验疗法博士后研究员。
Robert J. Cobuzzi, Jr. has served as a director since January 2020 and as our President and Chief Executive Officer since September 2020. Prior to joining Diffusion, Dr. Cobuzzi served as Advisor of the Mitochondrial Disease Research Program at the Children's Hospital of Philadelphia, an internationally recognized hospital and research center devoted to children, from January 2019 to April 2020 and as President and Chief Executive Officer of MitoCUREia, Inc., an affiliated company, from July 2019 to July 2020. From 2005 to 2018 Dr. Cobuzzi served in various roles at Endo International PLC, a specialty branded and generic pharmaceuticals manufacturer, most recently serving as President of Endo Ventures Ltd. Dr. Cobuzzi currently serves as Chairman of the Business Development Board of Sunstone Life Science Ventures, an early-stage, European focused investor in human therapeutics. Dr. Cobuzzi received his Bachelor of Arts in Biochemistry and Art History from Colby College and his Ph.D. in Molecular and Cellular Biochemistry from Loyola University Chicago. He served as a Post-doctoral Fellow in Experimental Therapeutics at Roswell Park Cancer Institute.- Robert J.Cobuzzi，Jr.自2020年1月起担任董事，自2020年9月起担任我们的总裁兼首席执行官。在加入Diffusion之前，Cobuzzi博士于2019年1月至2020年4月担任费城儿童医院线粒体疾病研究计划的顾问，该医院是一家国际知名的儿童医院和研究中心，并担任Mitocureia，Inc.的总裁兼首席执行官，关联公司，从2019年7月至2020年7月。2005年至2018年，Cobuzzi博士在专业品牌和仿制药制造商Endo International plc担任过各种职务，最近担任Endo Ventures Ltd.的总裁。Cobuzzi博士目前担任Sunstone Life Science Ventures的业务开发委员会主席，这是一家早期阶段的专注于人类疗法的欧洲投资者。Cobuzzi博士在科尔比学院获得生物化学和艺术史学士学位，并在芝加哥洛约拉大学获得分子和细胞生物化学博士学位。他曾担任Roswell Park Cancer Institute的实验疗法博士后研究员。
- Robert J. Cobuzzi, Jr. has served as a director since January 2020 and as our President and Chief Executive Officer since September 2020. Prior to joining Diffusion, Dr. Cobuzzi served as Advisor of the Mitochondrial Disease Research Program at the Children's Hospital of Philadelphia, an internationally recognized hospital and research center devoted to children, from January 2019 to April 2020 and as President and Chief Executive Officer of MitoCUREia, Inc., an affiliated company, from July 2019 to July 2020. From 2005 to 2018 Dr. Cobuzzi served in various roles at Endo International PLC, a specialty branded and generic pharmaceuticals manufacturer, most recently serving as President of Endo Ventures Ltd. Dr. Cobuzzi currently serves as Chairman of the Business Development Board of Sunstone Life Science Ventures, an early-stage, European focused investor in human therapeutics. Dr. Cobuzzi received his Bachelor of Arts in Biochemistry and Art History from Colby College and his Ph.D. in Molecular and Cellular Biochemistry from Loyola University Chicago. He served as a Post-doctoral Fellow in Experimental Therapeutics at Roswell Park Cancer Institute.
- William K. Hornung
William K.Hornung自2018年9月起担任我们的首席财务官。在被任命为首席财务官之前，Hornung先生于2017年7月至2018年9月担任Diffusion的首席商务官。此前，Hornung先生于2014年6月至2015年11月担任Contravir Pharmaceuticals的首席财务官，并帮助该公司在纳斯达克上市，并筹集了近3000万美元。在加入Contravir之前，从2002年到2014年，Hornung先生在PTC Therapeutics担任越来越重要的职位，最近的职位是从2012年4月到2014年3月担任财务副总裁。在PTC Therapeutics工作期间，他负责IPO过程，筹集了超过10亿美元的资金。从1998年到2002年，Hornung先生在Elan Pharmaceuticals（前身是Liposome Company）担任各种财务职务。在Liposome and Elan任职期间，他负责该公司位于英国的欧洲总部的战略规划和运营。在他职业生涯的早期，Hornung先生在一家临床研究机构工作，在那里他负责项目管理和公司的几乎所有财务方面。Hornung先生拥有William Paterson State University of New Jersey会计理学学士学位。
William K. Hornung serves as our Chief Financial Officer, a position he has held since September 2018. Prior to his appointment as Chief Financial Officer, Mr. Hornung served as the Chief Business Officer at Diffusion from July 2017 through September 2018. Previously, Mr. Hornung served as Chief Financial Officer of Contravir Pharmaceuticals from June 2014 to November 2015 and helped the company up-list to Nasdaq and raise nearly $30 million. Prior to Contravir, from 2002 through 2014 Mr. Hornung held positions of increasing responsibility with PTC Therapeutics, most recently serving as Vice President of Finance from April 2012 to March 2014. While at PTC Therapeutics he oversaw the IPO process and raised more than $1 billion. From 1998 through 2002 Mr. Hornung was with Elan Pharmaceuticals formerly The Liposome Company in various financial roles. At Liposome and Elan he was responsible for strategic planning and operations of the company's UK-based European headquarters. Earlier in his career Mr. Hornung worked for a clinical research organization where he was responsible for project management and nearly all financial aspects of the company. Mr. Hornung holds a Bachelor of Science in Accounting from the William Paterson State University of New Jersey.- William K.Hornung自2018年9月起担任我们的首席财务官。在被任命为首席财务官之前，Hornung先生于2017年7月至2018年9月担任Diffusion的首席商务官。此前，Hornung先生于2014年6月至2015年11月担任Contravir Pharmaceuticals的首席财务官，并帮助该公司在纳斯达克上市，并筹集了近3000万美元。在加入Contravir之前，从2002年到2014年，Hornung先生在PTC Therapeutics担任越来越重要的职位，最近的职位是从2012年4月到2014年3月担任财务副总裁。在PTC Therapeutics工作期间，他负责IPO过程，筹集了超过10亿美元的资金。从1998年到2002年，Hornung先生在Elan Pharmaceuticals（前身是Liposome Company）担任各种财务职务。在Liposome and Elan任职期间，他负责该公司位于英国的欧洲总部的战略规划和运营。在他职业生涯的早期，Hornung先生在一家临床研究机构工作，在那里他负责项目管理和公司的几乎所有财务方面。Hornung先生拥有William Paterson State University of New Jersey会计理学学士学位。
- William K. Hornung serves as our Chief Financial Officer, a position he has held since September 2018. Prior to his appointment as Chief Financial Officer, Mr. Hornung served as the Chief Business Officer at Diffusion from July 2017 through September 2018. Previously, Mr. Hornung served as Chief Financial Officer of Contravir Pharmaceuticals from June 2014 to November 2015 and helped the company up-list to Nasdaq and raise nearly $30 million. Prior to Contravir, from 2002 through 2014 Mr. Hornung held positions of increasing responsibility with PTC Therapeutics, most recently serving as Vice President of Finance from April 2012 to March 2014. While at PTC Therapeutics he oversaw the IPO process and raised more than $1 billion. From 1998 through 2002 Mr. Hornung was with Elan Pharmaceuticals formerly The Liposome Company in various financial roles. At Liposome and Elan he was responsible for strategic planning and operations of the company's UK-based European headquarters. Earlier in his career Mr. Hornung worked for a clinical research organization where he was responsible for project management and nearly all financial aspects of the company. Mr. Hornung holds a Bachelor of Science in Accounting from the William Paterson State University of New Jersey.
- Christopher D. Galloway
Christopher D.Galloway自2020年10月起担任我们的首席医疗官。在加入Diffusion之前，加洛韦博士于2018年8月至2020年9月担任La Jolla Pharmaceutical Company重症监护高级医学总监，他主持并监督了拉霍亚的研究人员发起的合作研究计划，并支持了与Giapreza™；Angiotensin II的推出有关的商业和医疗团队，它已被美国食品和药物管理局批准作为血管收缩剂，以增加患有败血症或其他分布性休克的成年人的血压。在拉霍亚任职之前，加洛韦博士于2016年12月至2018年7月担任乐天医疗公司（Rakuten Medical Inc.，简称F/K/A Aspyrian Therapeutics，Inc.）全球临床开发医学总监，该公司是一家生物技术公司，致力于开发针对细胞的调查性免疫肿瘤疗法，并担任默克公司的医学事务总监，Inc.的免疫疗法部门（2015年8月至2016年11月）。加洛韦博士在德克萨斯大学加尔维斯顿分校获得医学博士学位，在北卡罗来纳州夏洛特的卡罗莱纳医学中心完成了急诊医学住院医师的实习，并获得了德克萨斯大学奥斯汀分校的生物学学士学位。他被授权在科罗拉多州从事医学工作，并且是美国急诊医学委员会的文凭。
Christopher D. Galloway has served as our Chief Medical Officer since October 2020. Prior to joining Diffusion, Dr. Galloway served as senior medical director in critical care for La Jolla Pharmaceutical Company from August 2018 to September 2020 where he chaired and oversaw La Jolla's investigator-initiated and collaborative research programs and supported the commercial and medical teams in connection with the launch of GIAPREZA™angiotensin II, which has been approved by the U.S. Food and Drug Administration as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. Prior to his time at La Jolla, Dr. Galloway served as medical director for global clinical development at Rakuten Medical Inc. (f/k/a Aspyrian Therapeutics, Inc.), a biotechnology company developing cell-targeting investigative immuno-oncology therapies, from December 2016 to July 2018 and as medical affairs director within Merck & Co., Inc.'s immunotherapy division from August 2015 to November 2016. Dr. Galloway received his doctor of medicine from the University of Texas Medical Branch at Galveston, completed his residency in emergency medicine at Carolinas Medical Center in Charlotte, NC, and received a B.A. in biology from the University of Texas at Austin. He is licensed to practice medicine in the State of Colorado and is a diplomate of the American Board of Emergency Medicine.- Christopher D.Galloway自2020年10月起担任我们的首席医疗官。在加入Diffusion之前，加洛韦博士于2018年8月至2020年9月担任La Jolla Pharmaceutical Company重症监护高级医学总监，他主持并监督了拉霍亚的研究人员发起的合作研究计划，并支持了与Giapreza™；Angiotensin II的推出有关的商业和医疗团队，它已被美国食品和药物管理局批准作为血管收缩剂，以增加患有败血症或其他分布性休克的成年人的血压。在拉霍亚任职之前，加洛韦博士于2016年12月至2018年7月担任乐天医疗公司（Rakuten Medical Inc.，简称F/K/A Aspyrian Therapeutics，Inc.）全球临床开发医学总监，该公司是一家生物技术公司，致力于开发针对细胞的调查性免疫肿瘤疗法，并担任默克公司的医学事务总监，Inc.的免疫疗法部门（2015年8月至2016年11月）。加洛韦博士在德克萨斯大学加尔维斯顿分校获得医学博士学位，在北卡罗来纳州夏洛特的卡罗莱纳医学中心完成了急诊医学住院医师的实习，并获得了德克萨斯大学奥斯汀分校的生物学学士学位。他被授权在科罗拉多州从事医学工作，并且是美国急诊医学委员会的文凭。
- Christopher D. Galloway has served as our Chief Medical Officer since October 2020. Prior to joining Diffusion, Dr. Galloway served as senior medical director in critical care for La Jolla Pharmaceutical Company from August 2018 to September 2020 where he chaired and oversaw La Jolla's investigator-initiated and collaborative research programs and supported the commercial and medical teams in connection with the launch of GIAPREZA™angiotensin II, which has been approved by the U.S. Food and Drug Administration as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. Prior to his time at La Jolla, Dr. Galloway served as medical director for global clinical development at Rakuten Medical Inc. (f/k/a Aspyrian Therapeutics, Inc.), a biotechnology company developing cell-targeting investigative immuno-oncology therapies, from December 2016 to July 2018 and as medical affairs director within Merck & Co., Inc.'s immunotherapy division from August 2015 to November 2016. Dr. Galloway received his doctor of medicine from the University of Texas Medical Branch at Galveston, completed his residency in emergency medicine at Carolinas Medical Center in Charlotte, NC, and received a B.A. in biology from the University of Texas at Austin. He is licensed to practice medicine in the State of Colorado and is a diplomate of the American Board of Emergency Medicine.
- William R. Elder
William R.Elder自2020年9月起担任我们的总法律顾问兼公司秘书。在加入Diffusion之前，Elder先生主要担任BillyVonelds，LLC的总裁兼首席执行官，该公司是一家长达一个赛季的日常幻想体育公司，他从2019年4月至2020年9月管理该业务的所有公司，法律和运营方面。从2020年7月到2020年9月，Elder先生还担任Diffusion的兼职顾问。从2011年到2019年2月，Elder先生担任国际律师事务所Dechert LLP的公司和证券助理，在那里，Elder先生的业务主要集中在为上市公司提供有关证券法和监管要求，公司治理事务以及股票和债务市场中的金融交易的咨询。他在宾夕法尼亚大学法学院获得法学博士学位，在维拉诺瓦大学获得金融硕士学位，在塔夫茨大学获得经济学学士学位。
William R. Elder has served as our General Counsel & Corporate Secretary since September 2020. Prior to joining Diffusion, Mr. Elder principally served as president and chief executive officer of BillyVonElds, LLC, a season-long and daily fantasy sports company, where he managed all corporate, legal, and operational aspects of the business from April 2019 to September 2020. From July 2020 to September 2020 Mr. Elder also served as a part-time consultant to Diffusion. From 2011 to February 2019 Mr. Elder served as a corporate and securities associate for Dechert LLP, an international law-firm, where Mr. Elder's practice focused primarily on counseling public companies on securities laws and regulatory requirements, corporate governance matters, and financial transactions in the equity and debt markets. He received his J.D. from the University of Pennsylvania Law School, an M.S. in finance from Villanova University, and a B.A. in economics from Tufts University.- William R.Elder自2020年9月起担任我们的总法律顾问兼公司秘书。在加入Diffusion之前，Elder先生主要担任BillyVonelds，LLC的总裁兼首席执行官，该公司是一家长达一个赛季的日常幻想体育公司，他从2019年4月至2020年9月管理该业务的所有公司，法律和运营方面。从2020年7月到2020年9月，Elder先生还担任Diffusion的兼职顾问。从2011年到2019年2月，Elder先生担任国际律师事务所Dechert LLP的公司和证券助理，在那里，Elder先生的业务主要集中在为上市公司提供有关证券法和监管要求，公司治理事务以及股票和债务市场中的金融交易的咨询。他在宾夕法尼亚大学法学院获得法学博士学位，在维拉诺瓦大学获得金融硕士学位，在塔夫茨大学获得经济学学士学位。
- William R. Elder has served as our General Counsel & Corporate Secretary since September 2020. Prior to joining Diffusion, Mr. Elder principally served as president and chief executive officer of BillyVonElds, LLC, a season-long and daily fantasy sports company, where he managed all corporate, legal, and operational aspects of the business from April 2019 to September 2020. From July 2020 to September 2020 Mr. Elder also served as a part-time consultant to Diffusion. From 2011 to February 2019 Mr. Elder served as a corporate and securities associate for Dechert LLP, an international law-firm, where Mr. Elder's practice focused primarily on counseling public companies on securities laws and regulatory requirements, corporate governance matters, and financial transactions in the equity and debt markets. He received his J.D. from the University of Pennsylvania Law School, an M.S. in finance from Villanova University, and a B.A. in economics from Tufts University.